Come learn the latest in clinical thyroidology and thyroid-related basic investigation in a setting that will promote social and scientific exchange with your colleagues from around the world.

This year’s annual meeting program will once again bring together the best in basic and clinical thyroidology. Each day will include clinical and basic “tracks,” with symposia and Meet the Professor sessions selected to interest everyone attending. Since many of you are interested in both clinical and basic investigation in your discipline, we have tried to “stagger” these sessions to allow you to attend both types of symposia in a given area, such as thyroid cancer. Selected symposia, lectures, oral abstract sessions, poster sessions, and the prize lectures, however, still allow us all to come together for common sessions on each day.

For the first time this year, we asked those submitting an abstract to designate it as either clinical or basic. Reflecting the strength of our society, there was an almost even split between basic and clinical abstracts. Although the abstract categories were modified this year to better reflect current thyroid investigation, there are many examples of research that crosses traditional disciplines. The oral abstract and Poster Plus sessions are built around common themes, sometimes combining basic and clinical investigation.

We are especially pleased by the strong and diverse industry-supported CMES (Continuing Medical Education Symposia) being offered this year. In the newly created position of CMES Coordinator, Ian Hay, with help from the program chairs, worked to develop the symposia with our industry sponsors. Topics and speakers were selected to complement and enhance the overall program.

It is difficult to specify program highlights, as each day is filled with outstanding symposia, talks, and poster sessions, but here are some of the “can’t miss” events:

• Clinical symposia will include the use of KI to protect the thyroid in the event of a nuclear incident, novel therapies for thyroid cancer, radiation in thyroid cancer therapy, manifestations of Graves’ disease, thyroid autoimmunity-associated conditions, thyroid disease and pregnancy, and thyroid Grand Rounds.

• The Laboratory Committee has organized a case-based forum to look at the interface between the clinician and laboratory in evaluating thyroid disorders.

• A special symposium will feature a “bench to bedside” presentation on thyroid hormone metabolism for the clinician, coupled with a presentation on thyroid hormone...
President's Message
continued from page 1

One major change that you will have noticed this year is the increased visibility of our Association. Our Association has become more nimble and responsive to outside issues, largely thanks to the tireless efforts of our Public Affairs Director, Edie Stern, who has kept us abreast of thyroid-related issues in the public domain and in the legislature. One crowning achievement has been our success in encouraging the passage of legislation to facilitate KI stockpiling and distribution in case of nuclear emergencies—a cause that our Association has championed for more than 20 years! Our website continues to be our flagship for member support and increasing the visibility of our organization. I envisage that our new initiatives for patient support and outreach will continue to mature as we forge new collaborative relationships with patient organizations. You will notice a number of new initiatives at the upcoming Los Angeles meeting. These include:

- The formation of a “Women in Thyroidology” group that plans to meet before the opening reception to encourage the enrollment and mentoring of new women members—a sorely underrepresented segment of our Association.
- The results of new CMES guidelines being implemented by the Program Committee that are similar to those used by the Endocrine Society and that should ensure the design of high-quality programs that complement the original science being presented at the meeting.
- Presentation at the Business Meeting of the Bylaws initiative for competitive elections for the President and Council members.

Creation of a new Endowment initiative to fund “meet the professor” sessions.

Possibly the most controversial—consideration of a new logo for the Association.

For many years to come, our Association will owe a deep debt of gratitude to Past President Bill Chin’s foresight in spearheading the process to develop the Strategic Plan. Since the inception of the Plan, our Association has clearly become more flexible, democratic, and outward-looking. Member and patient services are more efficient and accessible, and our new attitude of outreach and visibility is truly living up to our mission “to provide outstanding leadership in thyroidology.”

I wish to thank all of you for the support that you have given me this year. I especially want to commend the efforts of our insightful and hard-working Secretary, Paul Ladenson. Paul is the rock that moors our Association to our core mission. Paul’s wise and knowledgeable counsel and guidance have been invaluable to me. He is a truly effective spokesperson for our Association.

The last couple of weeks before the Los Angeles meeting promise to be productive, challenging, and very busy for all our officers, Council members, and committees. During this time I will be working closely with Peter Singer to effect a smooth transition of the presidency in October.

Respectfully submitted,

Carole Spencer, PhD, FACB

Program Update - Los Angeles Annual Meeting
continued from page 1

and mood disorders presented by a prominent psychiatrist.

- Basic symposia will include thyroid hormone action during development, TSH receptor and autoimmunity, thyroid hormone receptor cofactors, mechanisms of thyroid growth and oncogenesis, thyroid hormone regulation of metabolism, and thyroid hormone receptor isoform-specific regulation.

- Several talks will explore the thyroid receptor as a therapeutic target for conditions such as hyperlipidemia and obesity.

- The latest tools in biomedical research will be presented in a special symposium, several Meet the Professor sessions, and the “state of the art lecture” by Christopher Glass (University of California, San Diego) on the role of nuclear receptors in inflammation and atherosclerosis.

I look forward to sharing with you in this exciting program.

Greg Brent
Co-Chair, Program
Chair, Local Arrangements

Congress supports thyroid research, and pharmaceutical and laboratory industries care about our clinical and research work. For 79 years, ATA members have led the way at the bench and the bedside, making the majority of significant basic, clinical, and epidemiological research advances seen in thyroidology. During the past year, our society has expanded its longstanding role in public health awareness and advocacy—moving beyond the traditional and very important topics of iodine deficiency and various forms of thyroid quackery to the current “hot” issues of screening for thyroid dysfunction, thyroid radioprotection with potassium iodide, FDA approval of thyroxine preparations, and appropriate allocation of NIH resources for thyroid research.

Patients have always looked to the ATA for advice and support. Our office fields hundreds of patient requests for information and referral each year. However, the ATA has been ambivalent about accepting broader responsibility for the education of patients with thyroid disease, supporting them and their families, and increasing public thyroid disease awareness. Fortunately, a handful of our members—recognizing the extraordinary need and enormous potential for good—have individually shouldered this responsibility, with support from patients and their families. Larry Wood has been a pioneer, founding the Thyroid Foundation of America and directing that association throughout its 17-year existence. Sheldon Rubenfeld and his successor, Steve Sherman, led the once-effective Thyroid Society for Education and Research. And many other members have dedicated time and effort to these organizations and others led by highly dedicated lay leaders like Diana Meltzer Abramsky of the Thyroid Foundation of Canada, Gary Bloom of ThyCa: Thyroid Cancer Survivors’ Association, Nancy Patterson of the National Graves’ Disease Foundation, and Joan Shey of the Light of Life Foundation. These organizations have accomplished a great deal: developing educational resources, heightening public awareness of thyroid disease, and providing individual counsel and support to tens of thousands of thyroid patients. The ATA has been generally supportive of their efforts, but in an official sense, rather uninvolved.

The recent collapse of the Thyroid Society should remind us just how fragile the support for these associations really can be—depending on a few ultra-dedicated professional and lay leaders, philanthropic support, and talented staff members who have other nonprofit leadership opportunities. If these responsible public voices falter, there won’t be public silence about thyroid disease. The Dr. Wilsons of this world will fill the vacuum.

Consequently, recognizing our mission and societal mandate, many ATA members now believe that we must become more actively involved in thyroid patient education and advocacy. Our society must consider this issue very carefully. What should be our specific goals and programs? How can we ensure that they do not diminish commitments to our traditional clinical and scientific missions? And who, if anyone, should be our partners in achieving our patient education and support aims? We need a vibrant, thoughtful debate.

Paul W. Ladenson, MD

 ATA Council Highlights
Executive Council Meeting
San Francisco - June 20, 2002

Annual Meeting: Program Committee Co-Chair Greg Brent reported fewer abstract submissions than in 2001, but high quality. Topic times will be staggered to allow attendees to hear both the clinical and basic coverage of the same topic. The strong clinical program will be specially marketed to Los Angeles area physicians, who can sign up for the whole program or just the weekend.

Nominating Committee: Thanking the Committee for its excellent work, Council approved a strong slate of candidates for this summer’s first competitive elections for President and Council members, and noncompetitive nominees for Secretary and Treasurer. The Bylaws will have to be updated to reflect this new election process.

Finances: ATA’s investments are doing reasonably well despite the rollercoaster stock market. An ad hoc web site committee should consider whether to accept advertising on the ATA site.

Membership Committee: Council voted to explore considering applications from physicians and scientists with serious interest, but not necessarily published work on the thyroid, and from non-doctoral qualified health care professionals with a commitment to thyroidology. The committee reemphasized that more women members should be recruited.

Patient Education and Advocacy Committee: A task force will be created to reexamine the ATA’s role in patient education, support, and advocacy. The Committee is considering two offers to prepare thyroid awareness videos.

Lab Services Committee: Three upcoming annual meeting presentations related to laboratory services will be posted to the ATA web site for use by members.

Potassium Iodide (KI) Symposium: An ATA sponsored symposium will emphasize practical aspects of KI distribution and education on February 28, 2003, in Washington, DC, for a target audience of government officials and scientists responsible for KI distribution and emergency planning. (AACE has accepted the ATA’s invitation to co-sponsor this conference with ATA.)

New logo: Council approved exploring the possibility of a new ATA logo, with input from membership at the Annual Meeting.
74th Annual Meeting: Local Arrangements Update

The 74th Annual Meeting at the Millennium Biltmore Hotel in Los Angeles is here. A full schedule of social programs has been planned:

- Those arriving on Wednesday afternoon can follow the sounds of the Mariachi band to a special afternoon activity planned in the exhibit area, where refreshments will reflect a California flavor.
- The evening opening reception will be held in the Crystal Ballroom, with entertainment by our own Joe DiStefano’s jazz combo.
- Be sure to sign up for Thursday evening, when we will travel to Universal Studios for a private “backlot” tour. You will see the places where many of your favorite movies were filmed, from “Psycho” to “Gladiator.” A ride on “Back to the Future” and a buffet dinner under the stars with dancing to contemporary music will complete the evening.
- Friday evening will feature a Continuing Medical Education program as well as a special California wine tasting. A number of vineyards will be represented, to give you an opportunity to taste California’s best and even arrange to have your favorite wines sent to your home.
- The banquet on Saturday evening will be back in the Crystal Ballroom, with a wonderful dinner and dance planned.

Each attendee will get a list of local attractions and evening entertainment suggestions, along with maps and tips on how to get around Los Angeles. You can also find information about local excursions on the ATA web site. Downtown Los Angeles is accessible to major freeways for car trips to Disneyland, San Diego, and Santa Barbara.

In the last issue of the SIGNAL, I'd promised to tell you a surprise about Los Angeles, and it’s just a few steps from the Millennium Biltmore Hotel. The surprise is the Pershing Square Metro Red Line Subway Station. This clean, safe subway train will take you from the hotel to entertainment centers in Hollywood and Universal City.

See you in LA!

— Greg Brent
Co-Chair, Program Chair, Local Arrangements

For the first time, our exhibit hall will open on Wednesday afternoon, during registration and before the welcome reception. On October 9, come register and then enjoy your first taste of Southern California! The meeting registration desk will open outside the exhibit hall at 2:00 pm. After your long day of traveling, we will have refreshments and a Mariachi band inside the exhibit hall so you can relax and chat with colleagues and industry representatives.

We would like to acknowledge our exhibitors thus far:

Abbott Laboratories
American Association of Clinical Endocrinologists
Brahms Diagnostica, LLC
E-mail retrieval service-supported by KRONUS, Inc.
Endocrine Nurses Society
The Endocrine Society
Esaote Pie Medical
Genzyme, Inc.
KRONUS, Inc.
Light of Life Foundation
Lippincott Williams & Wilkins
Mary Ann Liebert, Inc.
Monarch/Jones Pharmaceuticals
National Graves’ Disease Foundation
Nichols Institute Diagnostics
Saunders & Mosby
ThyCa: Thyroid Cancer Survivors’ Association
Thyroid Disease Manager

CMES Programs

**Thursday, October 10, 2002**
6:00 - 7:45 am  
**Defining Thyroid Hypofunction: Perspectives from Populations and the Clinic**  
“Early Riser” CME Symposium and breakfast supported by an unrestricted educational grant from Abbott Laboratories

**Friday, October 11, 2002**
6:00 - 7:45 am  
**Expanding the Utility of rhTSH in Benign and Malignant Thyroid Disease**  
“Early Riser” Symposium and Breakfast supported by an unrestricted educational grant from Genzyme Therapeutics

**Friday, October 11, 2002**
6:00 - 7:00 pm  
**The role of I-123 in the Management of Differentiated Thyroid Cancer**  
CME Symposium, wine tasting, and poster session supported by an unrestricted educational grant from MDS Nordion

**Saturday, October 12, 2002**
6:00 - 7:45 am  
**Optimizing Thyroid Hormone Replacement Therapy**  
“Early Riser” CME Symposium and breakfast supported by an unrestricted educational grant from Monarch Pharmaceuticals

**Sunday, October 13, 2002**
6:00 - 7:45 am  
**Should Mild Thyroid Failure in Patients with Cardiovascular Disease Be Treated?**  
“Early Riser” CME Symposium and breakfast supported by an unrestricted educational grant from Abbott Laboratories
President Carole Spencer sounded the call in her recent letter urging that ATA members encourage women colleagues to join the Association, mentor new women members, and nominate women members for leadership roles. Now ATA Council member Virginia Sarapura has risen to the challenge of diversifying ATAs membership with more women and increasing women's visibility within the Association. She and President Spencer have initiated the ATA “Women in Thyroidology” group.

All women attending the annual meeting in Los Angeles are invited to the group’s inaugural gathering on Wednesday, October 9 from 5:00 to 6:00 pm in the Tiffany Room at the Millennium Biltmore Hotel (see accompanying letter of invitation). There will be a short presentation about the need and purpose for the group. Then attendees will be invited to list their contact information and interests, and to sign up to help organize the group, mentor a new woman member, or be mentored by an experienced member.

After the meeting, mentors and mentees will be matched and the group organizers will get to work planning ways to increase female applicants and to propose more women for leadership.

2003 Program Chair Rebecca Bahn comments, “This group will promote mentoring and foster a greater sense of belonging to the organization. With this will come increased diversity of participation and an overall strengthening of the ATA.”

Longtime ATA member Valerie Anne Galton says, “The creation of a ‘Women in Thyroidology’ group is an excellent idea and one that will not only benefit those in early stages of their careers, but provide a forum for all women interested in our favorite gland. Congratulations to Carole and Virginia for their vision and motivation. I look forward enthusiastically to participating in this new endeavor.”

2002 Annual Meeting Program Co-Chair Greg Brent writes, “I am very enthusiastic about the idea of a ‘Women in Thyroidology’ group. I agree that with Carole’s focus and presidency, this would be a great inaugural year....We have some exceptionally accomplished women clinicians and basic scientists who would be great mentors.”

Dear Colleague,

We would like to invite all interested women ATA members attending the ATA annual meeting to a special gathering to discuss the creation of a “Women in Thyroidology” group. The gathering will take place in Los Angeles on Wednesday October 9 from 5:00 to 6:00 pm, right before the Welcome Reception, and will be held in the Tiffany Room at the Biltmore Hotel.

The purposes of “Women in Thyroidology” will be to promote women ATA members to take on leadership roles, as well as to encourage more women to join the ATA and to mentor new Associate and Active women members to help them establish stronger links with the ATA.

Whether you are a longstanding ATA member or will be joining this year, we need your help and support to make this effort successful. We hope that you will attend this gathering. If you have any questions or comments, please feel free to contact Virginia Sarapura (phone 303 315-8195, fax 303 315-8195, e-mail virginia.sarapura@uchsc.edu).

We look forward to meeting with you on October 9.

Sincerely,

Virginia Sarapura  
Carole Spencer

ATA Council Member  
ATA President

Bobbi Smith

Bobbi Smith  
Executive Director

Campaign for Thyroid Discovery...ATA climbs to halfway mark!

Exciting news! In July, Pepper Davis, Chair of the Campaign for Thyroid Discovery, and Lew Braverman, met with Genzyme executives in Cambridge, Massachusetts to discuss the Campaign for Thyroid Discovery. Drs. Davis and Braverman are pleased to report that Genzyme has pledged $25,000 for this year, giving Genzyme a total of $50,000 donated to the Campaign.

In addition, Abbott Laboratories has now contributed $800,000 of its $1 million five-year pledge to the Campaign. With such tremendous support, the campaign has reached halfway to the goal of $3 million.

Many thanks to all of you who have contributed this year to the Campaign. If you are interested in pledging and have questions about how you can give, please call Roslyn McKee at 703 998-8890.

Virginia Sarapura  
Bobbi Smith
Are you interested?

If you are interested in serving on an ATA committee or otherwise becoming more involved in the Association’s work, please contact Secretary Paul Ladenson at 410 955-3663 or ladenson@jhmi.edu.

New on the ATA web site

www.thyroid.org

ATA Members’ Services
This new section is restricted to ATA members. The first time you use Members' Services, you can log in just by typing your name. During that first log-in, you’ll choose your own password for future access. Use the members-only section for:
- Your member record and specialty areas — you can update your own information
- ATA members by name, city, or state
- On-line directory of all members
- THYROID journal on-line
- SIGNAL newsletter on-line
- ATA Bylaws
- ATA Strategic Plan

74th Annual Meeting Information
Click on the palm tree logo for:
- Registration information
- Registration link
- Hotel reservation link
- Scientific program details
- Meeting at a glance
- Los Angeles highlights

ATAs Signal 
October 2002 
Page 7

Honors and Awards to ATA Members

ATA members have been successive presidents of the American Association of Clinical Endocrinologists (AACE). Rhoda Cobin served as president for 2001-02, and Hossein Gharib is serving for 2002-03. Both presidents have increased collaboration between AACE and ATA.

Marvin Gershengorn is Director of the Division of Intramural Research at the National Institute of Diabetes and Digestive and Kidney Diseases. He had formerly chaired the Program in Physiology, Biophysics, and Molecular Medicine at Cornell’s Weill Medical College in New York.

Michael Kaplan received the first-ever Outstanding Clinician Award from the American Association of Clinical Endocrinologists.

Paul Ladenson has been chosen as President-Elect of the Association of Subspecialty Professors (ASP), the organization representing subspecialty internal medicine divisions at U.S. academic health centers. Since 1995, he has served as one of two Endocrinology representatives on the Council of ASP, which promotes the interests of subspecialty internal medicine, facilitates cooperation within the academic medical and internal medicine communities, provides career development for division chiefs and fellowship training program directors, and assists accredited fellowship training programs.

Reed Larsen received the 2002 Edwin B. Astwood Lecture Award from The Endocrine Society, given for outstanding research in endocrinology. At the Endocrine Society’s 84th Annual Meeting in San Francisco in June, Dr. Larsen presented a plenary lecture on “Molecular Physiology and Pathology of Iodothyronine Deiodination.”

Also at the Endocrine Society Annual Meeting in June, Samuel Refetoff received the 2002 Robert H. Williams Distinguished Leadership Award. This award is presented in recognition of outstanding leadership in fundamental or clinical endocrinology, as exemplified by the recipient’s contributions and those of his trainees and associates, to teaching, research, and administration.

ATA Committee Chairs 2001-2002

Awards Committee, P. Reed Larsen
Bylaws Committee, Edward Merker
Standards of Care (Clinical Affairs) Committee, Susan J. Mandel
Development Committee, Elias C. Dow
Paul J. Davis, Campaign Chair
Education Committee, Anthony N. Hollenberg
Finance and Audit Committee, David H. Sarne
History and Archives Committee, Clark T. Sawin
Lab Services Committee, S. Thomas Bigos
Local Arrangements Committee, Gregory A. Brent

Membership Committee, Antonio C. Bianco
Nominating Committee, E. Chester Ridgway
Patient Advocacy and Education Committee, Alan P. Farwell
Program Committee, Gregory A. Brent, Basic Science Leonard Wartofsky, Clinical
Public Health Committee, Kenneth D. Burman Victor J. Bernet, Vice Chair
Publications Committee, Martin I. Surks
Research Committee, Sandra M. McLachlan
ATA members have long served as advisors, consultants, and speakers for thyroid patient support organizations. As an association, ATA has been working ever more closely with several highly regarded patient organizations. Through the work of Alan Farwell, David Cooper, and the rest of the Patient Education and Advocacy Committee, ATA has been seeking to formalize this cooperation through an Alliance of Thyroid Patient Societies. The Alliance will enable the groups to collaborate easily on joint projects, coordinate responses to issues, and support patient education and public awareness of thyroid disease.

**Patient organization events in Los Angeles**

A forum for patients with thyroid disease will be held on Friday October 11 from 6:00 - 8:00 pm at ATA's Millennium Biltmore Hotel headquarters in Los Angeles. The event, which is free and open to the public, will feature presentations by hypothyroid, hyperthyroid, and thyroid cancer patients and their physicians, followed by a question and answer session. The forum is being organized by the Thyroid Foundation of America and ATA, in conjunction with ThyCa: Thyroid Cancer Survivors’ Association, the National Graves’ Disease Foundation, and the Light of Life Foundation. A highly successful patient forum was held on the eve of last year’s ATA annual meeting in Washington. Although the event had had to be rescheduled along with the other meeting events, and despite the short notice, the session drew more than 100 attendees, some of whom were still asking questions hours after the formal presentations ended.

ThyCa and the National Graves' Disease Foundation will hold their annual meetings at the same time as ATA's, and within walking distance of the Millennium Biltmore Hotel. Many ATA members will speak at these meetings, and ATA members are welcome to attend their sessions. You can get information about these meetings at the web sites below.

**Patient organization descriptions**

Here are brief profiles of the four major U.S. organizations and the major organization in Canada—all of which ATA hopes to include in the Alliance.

Founded in 1985 with encouragement and support from ATA members, the **Thyroid Foundation of America** (TFA) was the first national association to support and educate patients with thyroid disease. TFA now receives more than 25,000 requests for information each year from patients across the U.S., and works with other patient groups and professional societies to make research advances more accessible to the public. In 1995, TFA Founder and President Larry Wood helped create Thyroid Federation International (TFI). TFI now includes 23 thyroid patient organizations in 19 countries, focusing on patient and public education about thyroid disorders throughout the world. Both TFA and TFI are concerned with international issues like iodine consumption programs, newborn thyroid screening in developing nations, and thyroid education for health professionals. TFA's web site is www.allthyroid.org. TFI's is www.thyroid-fed.org.

The oldest North American patient education association is the **Thyroid Foundation of Canada** (TFC), which was founded in 1980. The TFC promotes awareness and education about thyroid disease and raises funds for research. The 23 chapters around the country offer public education meetings with medical experts, a telephone help-line, and community education and publicity. The web site, with excellent patient education materials in both English and French, is www.thyroid.ca.

**ThyCa: Thyroid Cancer Survivors’ Association, Inc.**, founded in 1995, is an all-volunteer nonprofit organization, guided by a medical advisory council of renowned thyroid cancer specialists, offering support and information to thyroid cancer survivors, families, and health care professionals worldwide. ThyCa provides a network of free local support groups (including groups organized by diagnosis), one-on-one support, a low-iodine cookbook, and newsletters. ThyCa sponsors Thyroid Cancer Awareness Week (the third week of September), regional workshops, and an annual International Thyroid Cancer Survivors’ Conference. The web site, with details of this October's Los Angeles meeting, is www.thyca.org.

Founded in 1990, the **National Graves’ Disease Foundation** (NGDF) is a nonprofit, patient-led educational organization guided by an international multidisciplinary board of medical advisors. NGDF offers support and resources to Graves’ disease patients, their families, and health care professionals. NGDF organizes local support groups and trains their leaders, offers one-on-one support, and publishes bulletins on Graves'-related topics. Patient members of the Foundation have contributed generously to ATA’s Campaign for Thyroid Discovery. NGDF’s database of 10,000 potential research subjects is available to qualified researchers. The Foundation sponsors National Graves’ Disease Awareness Week (the third week of January) and an annual patient and family conference. The web site, which features a monitored bulletin board and has details on this October’s Los Angeles meeting, is www.ngdf.org.

The **Light of Life Foundation**, founded in 1997, strives to improve the quality of life for thyroid cancer patients, educate the public and professionals about thyroid cancer, and promote research and development to improve thyroid cancer care. Light of Life has strong ties to Memorial Sloan-Kettering Cancer Center. The Foundation offers support groups, gifts for hospitalized patients, a low-iodine cookbook, and an annual educational symposium, and raises funds for thyroid cancer research. The Medical Advisory Board gives an annual award to an outstanding thyroid cancer researcher. The web site is www.lightoflifefoundation.org.

All of the organizations’ web sites provide patient education materials and information resources.

Unfortunately, this year has seen the demise of another fine patient organization, the **Thyroid Society for Education and Research**. We hope that the remaining organizations will continue to thrive as members of the Alliance of Thyroid Patient Societies.
**Saul Hertz Endowment**

Given by his daughter, Barbara Hertz

Special gifts have been made to the American Thyroid Association this year to support the annual meeting. One of these gifts was made by Barbara Hertz to honor the memory of her father, eminent thyroidologist Saul Hertz. The ATA is grateful for this sponsorship, which will enable fellows to attend “Meet the Professor” luncheon workshops at no cost.

Saul Hertz (1905-1950) graduated Phi Beta Kappa from the University of Michigan and earned his MD at Harvard Medical School in 1929. After an internship and residency at Mt. Sinai Hospital in Cleveland, he joined the Thyroid Clinic at Massachusetts General Hospital and served as chief of the Thyroid Unit from 1931-43.

Over lunch in November 1936, Dr. Hertz asked MIT President Karl Compton a perceptive and historic question: Could iodine be made artificially radioactive? A few weeks later, Dr. Compton wrote Dr. Hertz that radioactive iodine “has a half period of decay of 25 minutes and emits gamma rays and beta rays (electrons) with a maximum energy of 2.1 million volts.” Working with MIT physicist Arthur Roberts, Dr. Hertz completed an innovative series of studies in rabbits on the metabolism of radioactive iodine. In January 1941, Drs. Hertz and Roberts were the first to administer cyclotron-produced iodine-131 to treat hyperthyroid patients. Dr. Hertz authored some 30 scientific publications, most dealing with endocrinology, and especially thyroid physiology, thyroid disease, and its treatment. In addition to his pioneering work with radioactive iodine, he studied the clinical application of radioactive phosphorus and influences of hormones on cancer using radio-isotopic techniques. Dr. Hertz was a man of high principles and courage. He devoted his life to scientific work and had a major impact on thyroid disease management.

Barbara Hertz, Dr. Hertz’s daughter, has initiated the annual meeting endowment. “I chose the American Thyroid Association for the Saul Hertz Endowment because I believe it has the integrity to honor my father with the historical unbiased truth of his contribution to the study and treatment of thyroid disease. The ATA is creating the opportunity with this endowment for a meet the professor luncheon, thus encouraging, supporting, and inspiring other researchers to demonstrate their courage in bringing their ideas to fruition.”

---

**ATA Research Grants Awarded**

The ATA is committed to supporting research into better ways to diagnose and treat thyroid disease. The generosity of members, patients, industry, and donors in the workplace has enabled the ATA to award thyroid research grants of over $500,000 since the inception of the Research Fund.

**Research Grant Recipients 2002**

- **Antonio C. Bianco, MD, PhD**
  Brigham and Women’s Hospital, Boston, Massachusetts
  *Type 2 Deiodinase-mediated Intracellular Thyrotoxicosis in Brown Adipocytes Is Critical for Energy Homeostasis and Adaptive Thermogenesis in Small Mammals*

- **Peter Kopp, MD**
  Northwestern University, Chicago, Illinois
  *Targeted Overexpression of a Dominant Negative Insulin Growth Factor I (IGF-1) in Thyroid Follicular Cells In Vivo*

Thank you to the Research Committee for their diligence in reviewing all the applications. A special thank you to **Chair, Sandra McLachlan** for her leadership on this committee.

Committee members:
- **Grant Anderson**
- **Peter Arvan**
- **Marla J. Berry**
- **Irwin L. Klein**
- **Ronald J. Koenig**
- **Mariusz W. Szkudlinski**
- **Marvin C. Gershengorn, Council Liaison**

---

**A New ATA Logo?**

In recent years, some have questioned whether the ATA current logo—long a unifying, identifiable symbol—still represents the Association accurately in 2002. Several concerns have been expressed. First, to some, the logo makes the ATA appear more tradition-bound than forward-looking. Second, the logo does not explain what the ATA is, as does our current motto, “Physicians and scientists dedicated to the research and treatment of thyroid diseases.” Third, the portrait Robert Graves’ implies commitment to only one form of thyroid disease. Fourth, the logo is not legible in the small sizes employed for our letterhead, envelopes, and publications.

Consequently, Council is considering a new logo and commissioning some possible designs for members to see and comment upon at the Annual Meeting in Los Angeles.

Please stop by the ATA booth at the Annual Meeting, look over the possibilities, and share your thoughts with the ATA Officers, Council, and Staff. The logo proposals will also be posted on our website after the Annual Meeting.
Greater Member Participation in New Election Process

The American Thyroid Association Executive Council, with the endorsement of ATA members attending the Washington, DC annual meeting, has opened the door to a democratic process that will be launched in the next few weeks. The membership directed the Nominating Committee to develop a scheme for competitive elections and directed the Bylaws Committee to make the needed changes to accommodate them with our bylaws.

For the first time in recent history, the ATA will have a competitive election for president-elect and directors. The secretary-elect and treasurer-elect positions remain unopposed. With the input of members responding, the Nominating Committee proposed the following slate of strong candidates. This was endorsed by Council at their June meeting in San Francisco (see pages 11-13 for candidate statements and pictures):

For President (Vote for 1)
1. Valerie Anne Galton
2. Clark Sawin

For Director (Vote for 2)
1. Rebecca Bahn
2. Bryan Haugen
3. Don St. Germain
4. Steve Sherman

Non-competitive Officer Candidates:
Secretary-elect Gregory Brent
Treasurer-elect Charles Emerson

Each active member will receive a Proxy Ballot in September to return to the Secretary to vote their preference at the ATA Annual Business Meeting.

Timeline:
September 2002 Active members receive a Proxy Ballot
September 2002 Coded proxy Ballot sent to Secretary in reply envelope provided
October 2002 Attendance and coded ballots tallied
Business Meeting Members in attendance can exchange proxy ballot for On-Site ballot, if desired
Final vote tallied and announced

Update on FDA-Approved Thyroxine Preparations

As of August 22, 2002, the FDA-approved brands of thyroxine were Synthroid, Levoxyl, and Unithroid. Approved generic formulations were Levo-T (Mova Pharmaceuticals), Novothyrox (Gerapharm), and levothyroxine sodium tablets (Mylan Pharmaceuticals).

The FDA is still reviewing a New Drug Application for Levothyroid. Levothyroid distribution remains under the FDA’s mandated slow phase-out until the drug is approved. The ATA Public Health Committee does not know of any additional generic drugs now under review.

The ATA web site’s thyroxine fact sheet, “How the Food and Drug Administration’s ruling on thyroxine products affects patients and physicians,” is at http://www.thyroid.org/publications/statements/01_11_07_fda_thyrox.html

Recently approved drugs are listed at http://www.fda.gov/cedr/approval/index.htm.

TRH (Thyrel®) Production Suspended

Production of Thyrel®, TRH (protirelin), has been halted as of July 2002. The manufacturer, Ferring Pharmaceuticals, says that it is modifying the manufacturing process for Thyrel® in order to meet newly mandated production guidelines. Since the development of ultrasensitive TSH assays, the indications for use of TRH for thyroid axis testing have become fairly limited. TRH is now rarely indicated for detection of thyrotoxicosis or hypothyroidism. However, results from a TRH stimulation test can sometimes be useful in special clinical situations, such as distinguishing TSH-secreting pituitary tumors from other forms of inappropriate TSH secretion and in subtle cases of central hypothyroidism. It is uncertain how long this processing modification will take. Ferring's information letter says, “Ferring will make every effort to implement these changes as soon as possible, but as with any pharmaceutical process, significant time is needed to make these manufacturing upgrades.” As no other company appears to produce TRH at this time, no replacement product is expected to be available until Thyrel® returns to the market.

- Vic Bernet and Ken Burman, Co-Chairs,
Public Health Committee
Valerie Anne Galton, Ph.D.
(Candidate for President-elect)

Candidate Statement: When I joined the Association in 1963 it was known as the American Goiter Association, a name which aptly described its original focus. Since then the name has been changed and the mission has been expanded and redefined such that the very first of its eleven goals is to support all aspects of thyroid research. This remarkable metamorphosis was in response to the changing needs of the 20th century. The ATA will undoubtedly be ready to respond to the challenges of the future with strong leadership and a clear sense of direction as provided by the strategic plan.

Biographical Note: Dr. Galton has been a member of the ATA since 1963. Over the years she has served on many ATA committees including those for Development, Awards and Research. She is also a past member and past chairman of the Program committee and from 1987 to 1991 she served as a member of the ATA Executive Council. In 2002 the ATA honored her with the Sidney H. Ingbar Distinguished Lectureship Award.

Dr. Valerie Anne Galton received her Ph.D. from the University of London in 1959 under the mentorship of Dr. R. Pitt-Rivers, at the National Institute for Medical Research, U.K. She came to the U.S. in 1959 to work with Dr Sidney H. Ingbar at the Thorndike Laboratory, Harvard Medical School. She joined the faculty of Dartmouth Medical School in 1961, where she has remained ever since, leading an active research program and teaching. She is also very committed to graduate and post-graduate education.

Clark T. Sawin, M.D.
(Candidate for President-elect)

Candidate Statement: I strongly support the development effort; efforts to expand membership, particularly efforts to bring in younger members; plans to fund fellows to attend the annual meeting; and plans to establish linkages with other groups, particularly the expansion of the public's knowledge of thyroid disease. Given the recognized high prevalence of thyroid disease, particularly in its subclinical forms, all of these efforts — the investigative and the clinical — need to be coordinated for the benefit of our patients.

Biographical Note: Dr. Sawin has been a member of the ATA for over 20 years, has served as member and chair of the Education Committee, has chaired the ATA History Committee for the past 14 years and has been the ATA Historian (and historical lecturer) for the past 10 years.

Dr. Clark Sawin graduated from Tufts Medical School in 1958 and, after several years’ service in the US Army, trained in endocrinology with Dr. E. B. “Ted” Astwood. After that he was Chief, Endocrinology and Diabetes at the Boston VA Hospital from 1966 to 1998 when he moved to Washington, DC, where he is now in charge of the Office of the Medical Inspector for the Veterans Administration's healthcare system (the Office is responsible for monitoring the quality of care for the system). Research interests include the history of thyroid disease and, for the past 20 years, the long-term epidemiology of thyroid disease in the Framingham Study including, for example, the prevalence of subclinical hypothyroidism and relationship of atrial fibrillation to subclinical hyperthyroidism.
Rebecca Bahn, M.D.
(Candidate for Director)

Dr. Bahn has been a member of the ATA since 1987 and has served on the Program and Nominating Committees. She was a member of the Program Committee for the 12th International Thyroid Congress held in Kyoto in 2001 and will serve as basic science Program Committee co-chair for the 2003 ATA meeting.

Dr. Rebecca Bahn is Professor of Medicine at Mayo Medical School and Consultant in the Division of Endocrinology at Mayo Clinic. She is a graduate of Mayo Medical School and completed her Internal Medicine and subspecialty training at that Institution. Dr. Bahn's clinical interests relate primarily to the treatment of Graves' ophthalmopathy and Graves' disease and she directs a laboratory-based program to study the pathogenesis of those disorders. She recently completed a term on the NIH Endocrinology Study Section and was past Chair of the Abbott Thyroid Research Advisory Council.

Bryan R. Haugen, M.D.
(Candidate for Director)

Dr. Haugen has been a member of the ATA since 1994 and is currently serving on the Program Committee for the 2002 American Thyroid Association Annual Meeting and on the editorial board for the journal THYROID. In 2003 Dr. Haugen will be co-chair of the Program Committee for the Annual Meeting.

Dr. Bryan Haugen is an Associate Professor of Medicine and Pathology and his administrative roles include Associate Director of the General Clinical Research Center, Assistant Chief in the Division of Endocrinology and Director of the Thyroid Tumor Program at the University of Colorado Health Sciences Center. He is also a member of the National Thyroid Cancer Treatment Cooperative Study Group. His many interests include: thyroid cancer, nuclear hormone receptors and the effects of retinoids on pituitary-thyroid function and educating thyroidologists.

Donald L. St. Germain, M.D.
(Candidate for Director)

Dr. St. Germain has been a member of the ATA since 1985 and served as Program Chair for the 1997 annual meeting in Colorado Springs. For the past 5 years he has served in an advisory capacity to the ATA Program Committee and is currently a member of the ATA Standards of Care Committee.

Dr. Donald St. Germain is currently Professor of Medicine and of Physiology and the Acting Chair of the Department of Medicine at Dartmouth Medical School. He joined the faculty there in 1984 after completing his fellowship training under Dr. Valerie Anne Galton and Dr. Robert Adler. He currently maintains an active, NIH-funded research program investigating the molecular mechanisms involved in the metabolism and action of thyroid hormones, and is particularly interested in their developmental effects. In addition to his research interest, Dr. St. Germain is actively involved in teaching in several basic science and clinical courses at Dartmouth Medical School, is the Director of the Dartmouth Community Medical School public education initiative, is a former member of the NIH Endocrinology Study Section, and maintains a consultative clinical practice in general endocrinology with an emphasis on thyroid disorders.
Steven Sherman, M.D.
(Candidate for Director)

Dr. Sherman has been an active member of the ATA since 1992, and has served on the Public Health and Education Committees. In 2000, he participated in the organization’s first Strategic Planning Retreat, contributing to discussions regarding public education efforts and membership.

Dr. Steven I. Sherman is an Associate Professor and Chairman ad interim of the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas M.D. Anderson Cancer Center. Other leadership roles he holds in the thyroid field include chairing both the NCCN Thyroid Carcinoma Consensus Guidelines Committee and the National Thyroid Cancer Treatment Cooperative Study Group, and he is a member of the editorial board of the *Journal of Clinical Endocrinology and Metabolism*. Additionally, he served from 1998-2001 as the Medical Director of The Thyroid Society, a leading patient education organization, and helped to build a strong linkage between this group and the ATA.

Gregory A. Brent, MD
(Secretary-elect)

Dr. Brent has been attending ATA annual meetings since 1986 and became a regular member of the ATA in 1988. He has served on the Program and Patient Education Committees, and chaired the Membership Committee. He has been a Director since 2001 and currently serves as Chair of the Local Organizing Committee for the 74th Annual Meeting and Co-Chair of the Program Committee. He is a former Associate Editor of Thyroid and is currently on the editorial boards of Molecular Endocrinology, Endocrinology, and Thyroid. He recently completed a term as a regular member of the National Institutes of Health Endocrinology Study Section. He was awarded the Van Meter Prize of the American Thyroid Association and the Knoll Mentor Award from The Endocrine Society.

Dr. Gregory Brent is Professor of Medicine and Physiology at UCLA School of Medicine, Chief of the Endocrinology and Diabetes Division of the VA Greater Los Angeles Healthcare System and Director of the Endocrinology Fellowship Program.

Charles H. Emerson, M.D
(Treasurer-elect)

Dr. Emerson, has been an active member of the ATA since 1976. In 1993 he served on the Bylaws Committee and from 1996-1998 he served on the Awards Committee. Dr. Emerson then went on to serve on the Membership Committee in 1998 and 1999.

Dr. Emerson is a Professor of Medicine at the University of Massachusetts Medical School. He received his MD from the University of Virginia in 1967 and completed Medical Residency at the Hospital of the University of Pennsylvania in 1970. As he was considering Endocrine Fellowships his interest in the thyroid was kindled by Dr. Gerald Burke’s review of the “Long Acting Thyroid Stimulator” of Graves’ Disease. Discussions of this remarkable disorder with Dr. Robert Utiger cemented this attraction. After an Endocrine Fellowship at Penn with Dr. Utiger he went to the University of Illinois in Chicago where he studied the metabolism of TRH. In 1980 he was recruited to the University of Massachusetts by Dr. Lewis Braverman. Dr. Emerson’s research and clinical interests have focused on the metabolism of thyroid hormones in the placenta and periphery, maternal and fetal thyroid function during and after pregnancy, the regulation of TRH and TSH as a function of age, sex hormone status and nutrition, and the physiological effects and clinical utility of recombinant human TSH.
ATA's one-day symposium “Public Health Strategies for Protecting the Thyroid with Potassium Iodide in the Event of a Nuclear Incident” will be held on Friday, February 28, 2003 at the Hyatt Regency Washington on Capitol Hill. ATA members will receive full registration information in the fall, but to whet your appetite:

The symposium’s objectives are to:
- Explain, in the context of the Chornobyl (Chernobyl) nuclear accident, how nuclear fallout that contains radioactive iodine can endanger the thyroid and how KI can protect it.
- Present current and impending federal policies on KI.
- Describe how European and U.S. state governments stockpile and distribute KI and educate their populations about its use.
- Improve collaboration with other individuals and agencies in optimizing KI use.

Tentative speakers and topics:

**Keynote Address**

Current Status of the Radiation Impact of the Chornobyl Nuclear Accident on the Thyroid  
Sir E. Dillwyn Williams, MD, FRCPath

Sources and Types of Radiation Affecting the Thyroid After a Nuclear Incident  
Andre Bouville, PhD

Biochemistry of Thyroidal Iodine  
John T. Dunin, MD

Physiology: Effects of Excess Stable Iodine on Thyroid Function  
Lewis E. Braverman, MD

Status and Direction of Federal Legislation and Policies on KI  
U.S. Congressman Edward J. Markey

The Polish Experience with KI After the Chornobyl Accident  
Jan Wolff, MD, PhD

Practical Experience with KI Distribution:  

The French Experience  
Yves Garcier, MD

The Irish Experience  
Peter P. Smyth, MSc, PhD

The Maryland Experience  
Michael J. Sharon and David L. Rogers, MD, MPH

Educating Professionals, the Public, and the Media about KI  
Jan K. Cárney, MD, MPH

Perspectives from the Food and Drug Administration  
David G. Orloff, MD

Hot Topic (speaker to be announced)

The day will end with a panel discussion moderated by David Becker, MD, addressing questions submitted by attendees before the symposium.

Congratulations to the hard-working Planning Committee of Drs. David Becker, Lew Braverman, John Morris, and Paul Ladenson. Thanks also to AACE (American Association of Clinical Endocrinologists), which is a funding partner for the symposium, and to Abbott Laboratories for a leadership support grant.
ATA SIGNAL

AMERICAN THYROID ASSOCIATION, INC.

Editor
Jeffrey R. Garber, MD
Contributing Editor
Edie Stern
Art Director
Kandra L. Files
Project Manager
Roslyn McKee

Officers and Directors 2001-2002
President
Carole A. Spencer, PhD, FACB
President-Elect
Peter A. Singer, MD
Treasurer
David S. Cooper, MD
Secretary
Paul W. Ladenson, MD
Directors
William W. Chin, MD
Virginia Sarapura, MD
Frederic E. Wondisford, MD
Sheue-yann Cheng, PhD
Marvin C. Gershengorn, MD
Elliot G. Levy, MD
Jeffrey R. Garber, MD
Gregory A. Brent, MD
Stephanie L. Lee, MD
John C. Morris, III, MD
Executive Director
Barbara (Bobbi) R. Smith, CAE

Published by the
American Thyroid Association
6066 Leesburg Pike, Suite 650
Falls Church, VA 22041
phone 703 998-8890
fax 703 998-8893
e-mail admin@thyroid.org
web www.thyroid.org

Office hours: 8:30 am - 6:00 pm Eastern time
Please notify the office (ideally, via the web site) whenever you change your address, phone or fax number, or e-mail address.

Contact Edie Stern with your story ideas or comments: 410 366-7292 or estern@thyroid.org

Newsletter Art & Design
Saratoga Graphics
7 Kaatskill Way
Ballston Spa, NY 12020
phone and fax 518 583-0243
e-mail kanlynnsprynet.com

UPCOMING SOCIETY MEETINGS

Clinical Endocrinology Update: 2002
The Endocrine Society
October 6-9, 2002
Portland, Oregon
contact: Beverly Glover
phone: 301 941-0200
fax: 301 941-0259
e-mail: bglover@endo-society.org
web: www.endo-society.org

ATA 74th Annual Meeting *
October 9-13, 2002
Millennium Biltmore Hotel
Los Angeles, California
* Two patient organization meetings being held in conjunction with the ATA meeting: *

* ThyCa 2002: 5th International Thyroid Cancer Survivors’ Conference
ThyCa: Thyroid Cancer Survivors’ Association
October 11-13, 2002
Los Angeles Athletic Club
Los Angeles, California
contact: Megan Stendebach
phone: 877 588-7904
fax: 503 905-9725
e-mail: conference@thyca.org
web: www.thyca.org

* Patient/Family Conference: A Bridge to Wellness X
National Graves’ Disease Foundation
October 11-13, 2002
Wyndham Checkers Hotel
Los Angeles, California
contact: Carole Johnson
phone: 510 724-3726
fax: 510 964-1767
e-mail: carolej@inreach.com
web: www.ngdf.org/conf2002.htm

Public Health Strategies for Protecting the Thyroid with Potassium Iodide in the Event of Nuclear Incident
American Thyroid Association and the Johns Hopkins University School of Medicine
February 28, 2003
Hyatt Regency Washington on Capitol Hill
Washington, DC
contact: Carol Kowarski
phone: 410 955-2959
fax: 410 955-0807
e-mail: ckowarski@jhmi.edu

6th European Congress of Endocrinology
April 24-30, 2003
Lyon, France
phone: +33 4 72 98 58 58
fax: +33 4 72 98 58 98
e-mail: info@endocrinology2003.com
web: www.endocrinology2003.com

American Association of Clinical Endocrinologists
May 14-18, 2003
San Diego Marriott Hotel and Marina
San Diego, California
web: www.aace.com

Endo 2003: 85th Annual Meeting of the Endocrine Society
June 4-7, 2003
Philadelphia, Pennsylvania
contact: Beverly Glover
phone: 301 941-0200
fax: 301 941-0259
e-mail: bglover@endo-society.org
web: www.endo-society.org

ATA 75th Annual Meeting
September 16-21, 2003
The Breakers
Palm Beach, Florida

AFES 2003 & AOTA 2003
November 30 - December 4, 2003
Raffles City Convention Centre
Singapore
contact: Celestine Lee or Jocelyn Fan
phone: 65 326 6690 or 65 321 3564
fax: 65 223 9789

American Association of Clinical Endocrinologists
April 28-May 2, 2004
Sheraton Boston & John B. Hynes Veterans Memorial Convention Center
Boston, Massachusetts
web: www.aace.com

Endo 2004: 86th Annual Meeting of The Endocrine Society
June 16-19, 2004
New Orleans, Louisiana
contact: Beverly Glover
phone: 301 941-0200
fax: 301 941-0259
e-mail: bglover@endo-society.org
web: www.endo-society.org

ATA 76th Annual Meeting
September 29-October 3, 2004
Westin Bayshore Resort & Marina Vancouver, British Columbia, Canada

13th International Thyroid Congress
October 30-November 4, 2005
Buenos Aires, Argentina

Copyright 2002 American Thyroid Association
74th ATA Annual Meeting
Los Angeles, California
October 9 - 13, 2002

On-line meeting registration: www.thyroid.org

Headquarters hotel:
Millennium Biltmore Hotel
506 South Grand Avenue
Los Angeles, California 90071
Reservations: 866 866-8086 or direct 213 624-1011

Questions?
Contact ATA headquarters:
phone 703 998-8890
fax 703 998-8893
e-mail admin@thyroid.org